Document is current
Any future updates will be listed below
-
Authors
Smith, Andrea L. https://orcid.org/0000-0002-9194-4888
Watts, Caroline G.
Henderson, Michael
Long, Georgina V.
Rapport, Frances
Saw, Robyn P. M.
Scolyer, Richard A.
Spillane, Andrew J.
Thompson, John F.
Cust, Anne E.
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (1135285)
National Health and Medical Research Council (1093017)
National Health and Medical Research Council (1093017)
National Health and Medical Research Council (1093017)
National Health and Medical Research Council (1141295)
Sydney Medical School Foundation (University of Sydney Medical Foundation)
- License Information
-
More Information
Article History
Received: 24 November 2021
Accepted: 19 September 2022
First Online: 1 October 2022
Declarations
:
: Approval to conduct this research was received from the Human Research Ethics Committee of The University of Sydney, Australia (Protocol Number: 2018/713).
: Informed consent was provided by all study participants to include de-identified data in reports and publications.
: RAS has received fees for professional services from F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline.GVL is a member of the executive committee for the Australian Clinical Practice Guidelines for the Diagnosis and Management of Melanoma. She is also a consultant advisor for Aduro Biotech Inc, Amgen Inc, Array Biopharma Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Evaxion Biotech A/S, Hexel AG, Highlight Therapeutics S.L., Merck Sharpe & Dohme, Novartis Pharma AG, OncoSec, Pierre Fabre, QBiotics Group Limited, Regeneron Pharmaceuticals Inc, SkylineDX B.V., and Specialised Therapeutics Australia Pty Ltd.RPMS has received honoraria for advisory board participation from MSD, Novartis and Qbiotics, speaking honoraria from BMS and Novartis and was a Working Party member of the current NHMRC Clinical Practice Guidelines for the Management of Cutaneous Melanoma (2018).JFT has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc, and travel and conference support from GSK, Provectus Inc and Novartis.
